AI-extracted from the 10-Q filed 2026-08-04 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Revenue grew 21% YoY to $189.9M on service and Liver-driven product growth, but net income fell 58% YoY to $14.7M as R&D nearly doubled, interest expense rose on a new finance lease, and management disclosed a material weakness in inventory controls.
Biggest Revenue Drivers
Net product revenue$111.2M+16% YoY
Higher sales volumes of OCS Liver disposable sets
Service revenue$78.8M+29% YoY
Increased usage of the National OCS Program (organ procurement, perfusion management and transplant logistics)
Biggest Revenue Drivers
Total revenue: $189.9M+21% YoY
Net product revenue$111.2M+16% YoY
Higher sales volumes of OCS Liver disposable sets
Service revenue$78.8M+29% YoY
Increased usage of the National OCS Program (organ procurement, perfusion management and transplant logistics)
Largest Expense Items
Selling, general and administrative$57.8M+31% YoY
Higher personnel costs from team expansion, $4.6M increase in professional/consultant fees including transaction-related costs, and increased facility/IT and depreciation costs
Total cost of revenue$76.8M+26% YoY
Higher freight costs and temporary inventory-related costs including strategic stocking and clinical trial product costs
Margins: Overall gross margin declined to 60% from 61% YoY, driven by a higher mix of lower-margin service revenue and a drop in product gross margin to 77% from 80% due to higher freight and temporary inventory-related costs.
Watch Items from the Filing
Management concluded disclosure controls were not effective due to a material weakness in internal controls over inventory movement within the manufacturing network.
Securities class action (Jewik/Collins) alleging misstatements during a 2023-2025 class period is proceeding to discovery after the court partially denied a motion to dismiss on July 21, 2026; damages unspecified.
Interest expense rose to $7.2M from $3.5M YoY, including $3.8M of new imputed interest on a 18-year, $374.6M finance lease for the Somerville, MA headquarters commencing January 2026.
No single customer accounted for more than 10% of revenue or accounts receivable in the quarter, indicating low customer concentration risk.
New headquarters project carries estimated total capital expenditures of $200M-$240M through 2030, with $12.7M already contractually committed.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
About TransMedics Group, Inc. (TMDX): stock profile, AI score and financials
TransMedics Group, Inc. (TMDX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores TMDX at 68.8/100 on a composite quality score built from its SEC filings, placing it at rank #285 of 2,925 stocks — the top 10% of the AI-ranked universe. TMDX scores in the top quartile across revenue growth (90.6), balance sheet strength (90.4), profitability (86.3). Areas of concern include institutional flow (27.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 21.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), TransMedics Group, Inc. reports quarterly revenue of $189.9M, net income of $14.7M, an operating margin of 12.5%. Top institutional holders of TMDX by reported 13-F value include BlackRock, FMR, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. TMDX trades on the Nasdaq exchange and files with the SEC under CIK 1756262. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TMDX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for TransMedics Group, Inc. directly from SEC EDGAR.